share_log
Reuters ·  May 2 16:26
Arrowhead Pharmaceuticals Inc - Pursuant to 2022 Agreement With Royalty Pharma Arrowhead Is Further Eligible to Receive $110 Mln From Royalty Pharma
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment